| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 22,687 | 26,490 | ||
| Accounts receivable, net | 5,000 | 5,571 | ||
| Inventory, net | 3,276 | 3,807 | ||
| Prepaid expenses | 2,365 | 2,216 | ||
| Total current assets | 33,328 | 38,084 | ||
| Property and equipment, net | 1,826 | 1,711 | ||
| Right-of-use assets | 890 | 1,103 | ||
| Other assets | 419 | 419 | ||
| Total assets | 36,463 | 41,317 | ||
| Trade payables | 3,784 | 1,902 | ||
| Accrued liabilities | 6,773 | 7,078 | ||
| Short-term lease liabilities | 129 | 123 | ||
| Other current liabilities | 224 | 221 | ||
| Total current liabilities | 10,910 | 9,324 | ||
| Long-term debt | 32,764 | 32,274 | ||
| Revenue base redemption liability | 502 | 358 | ||
| Long-term lease liabilities | 1,231 | 1,265 | ||
| Contingent earnout liability | 4,997 | 7,522 | ||
| Warrant and sepa liabilities | 12,784 | 9,997 | ||
| Total liabilities | 63,188 | 60,740 | ||
| Common stock, 0.0001 par value, 400,000,000 shares authorized at september30, 2025 and december31, 2024, respectively issued and outstanding, 49,891,299 and 31,279,264 shares at september30, 2025, and december31, 2024, respectively | 4 | 3 | ||
| Additional paid-in capital | 294,241 | 278,786 | ||
| Accumulated deficit | -320,970 | -298,212 | ||
| Total stockholders deficit | -26,725 | -19,423 | ||
| Total liabilities and stockholders deficit | 36,463 | 41,317 | ||
TriSalus Life Sciences, Inc. (TLSIW)
TriSalus Life Sciences, Inc. (TLSIW)